UNSPSC 51373334: Bupivacaine/fentanyl

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373334 Bupivacaine/fentanyl is a Commodity code that does not reflect the work actually being solicited under it in recent state and local opportunities. The code's nominal scope is a specific pharmaceutical compound; however, recent opportunities tagged under this code involve procurement of naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program implementation. These solicitations span pharmaceutical supply aggregation, community health support systems, and pharmacy benefit program redesign—none of which align with the specific opioid analgesic combination the code nominally describes. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance with Oregon participation). This mismatch between code designation and actual procurement scope suggests either inconsistent tagging or the code serving as a catch-all for pharmaceutical-related buys that fall outside more precise commodity classifications.

The geographic spread includes Florida, Texas, Minnesota, and Oregon. Recent opportunities consist of an IFB from Seminole County, Florida (posted June 30, 2026, response due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; a Request for Information from the Texas Health and Human Services Commission (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs; and an RFP from the Minnesota Department of Administration's Office of State Procurement on behalf of MMCAP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities. Given the absence of true bupivacaine/fentanyl procurement activity in the recent record and the category's mismatch with current solicitations, this code shows little relevant activity for vendors focused on the specific pharmaceutical combination it nominally represents.